

Protalix BioTherapeutics, Inc.  
Form 8-K  
February 13, 2013

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): February 13, 2013**

---

**Protalix BioTherapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

---

**Florida  
(State or other jurisdiction  
of incorporation)**

**001-33357  
(Commission File Number)**

**65-0643773  
(IRS Employer  
Identification No.)**



**Item 8.01. Other Events**

On February 13, 2013, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing that new clinical data on ELEYISO™ (taliglucerase alfa) will be presented at the 9th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2013 being held February 13-15 in Orlando, Florida. A copy of the press release is filed as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated February 13, 2013

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX BIOTHERAPEUTICS, INC.**

Date: February 13, 2013 By: /s/ David Aviezer, Ph.D.

Name: David Aviezer, Ph.D.

Title: President and Chief Executive Officer